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Abstract
Background: The PALB2 gene encodes a protein that plays a crucial role in maintaining genomic integrity. Germline
inactivating mutations in PALB2 are associated with an increased risk of breast and ovarian cancer. The prevalence and
spectrum of recurrent PALB2 germline mutations in breast and ovarian cancer patients from Poland is not clearly defined.
Methods: PALB2 exons were amplified from 460 BRCA1/2-mutation negative women with familial breast and/or ovarian
cancer and early-onset breast cancer using AmpliSeq technology and sequenced on an Ion Torrent PGM sequencer. In
addition, eight selected variants were genotyped using TaqMan assays in 807 BRCA1/2-mutation negative breast cancer
patients and 1690 healthy women.
Results: Two recurrent PALB2 mutations, c.172_175delTTGT and c.509_510delGA, were identified, along with one novel
mutation, c.347insT. In total, PALB2 pathogenic mutations were detected in 7/460 (1.5%) patients. Furthermore, in breast
and/or ovarian cancer patients, several single nucleotide variants (SNVs) were detected in the PALB2 coding region. In an
additional group of 807 patients, eight (1%) carriers of two pathogenic mutations, c.172_175delTTGT (0.5%) and
c.509_510delGA (0.5%), were identified. The c.509_510delGA mutation was not identified in healthy controls, while
c.172_175delTTGT was identified in 4/1690 (0.24%) of control women.
Conclusions: Germline mutations in the PALB2 gene were observed at a frequency of approximately 1.5% in Polish
breast and/or ovarian cancer patients. Our study confirms two recurrent PALB2 mutations; c.172_175delGA and
c.509_510delGA.
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Background
Breast cancer is the most frequently diagnosed malignancy
and the leading cause of cancer death in women world-
wide [1]. About 5–10% of breast and 10% of ovarian
cancers are thought to be hereditary [2]. Mutations in the
two main susceptibility genes, BRCA1 and BRCA2, ac-
count for 20% of hereditary breast cancer (HBC) and 30%
of hereditary breast and ovarian cancer (HBOC) [3]. Other
genes participating in DNA-damage response pathways,
including CHEK2, NBS1, ATM, BRIP1, and PALB2, are
also involved in HBC and HBOC [4, 5].
The PALB2 (MIM 610355, Partner and Localizer of
BRCA2) gene was identified in a search for novel com-
ponents of endogenous BRCA2 containing complexes
[6]. The PALB2 protein interacts with both BRCA1 and
BRCA2 through its N-terminal coiled-coil and C-
terminal WD-40 domains, respectively. These three pro-
teins form a “BRCA complex” in which PALB2 acts as a
bridge between BRCA1 and BRCA2. The “BRCA com-
plex” is crucial for initiating homologous recombination
in the DNA-damage response [6–8].
Biallelic inactivating germline mutations in the PALB2
gene lead to Fanconi anemia (Fanconi anemia type N),
whereas monoallelic mutations are associated with an
increased risk of breast, pancreatic, and possibly ovarian
cancer [9–14]. Germline mutations in PALB2 are
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responsible for 1–3.9% of HBC [15–26]. Similar to
BRCA2, germline mutations in PALB2 are also associ-
ated with hereditary predisposition to male breast can-
cer. To date, approximately 50 truncating mutations in
PALB2 have been detected in breast cancer families
worldwide.
The first breast cancer family-based association study
estimated that a relative risk of 2.3 (95% CI: 1.4–3.9) is
conferred by mutations of PALB2 [12]. Most recently,
Antoniou and colleagues. applied a modified segregation
procedure to show that the age-specific risk of breast
cancer in female mutation carriers overlaps with that
conferred by BRCA2 mutations [27].
In a previous study, we demonstrated that in a group
of 512 patients for whom targeted BRCA1/2 mutation
testing did not show any pathogenic variants, sequen-
cing of BRCA1/2 exons identified 52 carriers of muta-
tions [28, 29]. The aim of the present study was to
investigate the contribution of PALB2 germline muta-
tions in a group of 460 BRCA1/2-mutation negative
breast and/or ovarian cancer patients and identify the




DNA samples were chosen from the repository of the
Genetic Counseling Unit, Maria Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology in
Warsaw. In-depth interviews assessed personal and
familial cancer history. Healthy women with no known
history of cancer were enrolled from the National Colo-
rectal Cancer Screening Program. Patients comprised a
group of 460 BRCA1/2-mutation negative breast cancer
patients (with a median age of 43 years, range 17–68
years) and included 165, 103, and 192 women with
HBC, HBOC, and early-onset breast cancer (EOBC),
respectively [29]. This group of patients had undergone
full BRCA1/2 sequencing using the Ion AmpliSeq
BRCA1 and BRCA2 Panel (Thermo) on a PGM sequen-
cer as part of our previous study [29].
An additional group, comprising 807 selected BRCA1/
2-mutation negative women, was surveyed using TaqMan
SNP genotyping assays. This group had a median age of
48 years (range 20–85 years); included 322, 81, and 404
HBC, HBOC, and EOBC patients, respectively; and were
negative for 20 selected BRCA1/2 mutations, including 11
mutations in BRCA1, namely, c.66_67delAG, c.181T > C,
c.3756delGTCT, c.3700_3704del5, c.4035delA, c.3777delT,
c.4065delTCAA, c.4041delAG, c.5263delC, c.5213G > A,
and 5370C > T, and nine mutations in BRCA2, namely,
c.1408G > T, c.5946delT, c.5239insT, c.6447delTA,
c.5964delAT, c.7910del5, c.9382C > T, c.8924delT, and
c.9402delT [28].
NGS of PALB2
Genomic DNA was extracted from peripheral blood, as
previously described [28]. DNA concentrations were
determined using a Qubit 2.0 Fluorometer (Thermo)
and the dsDNA HS Assay Kit (Thermo). For library con-
struction, the Ion AmpliSeq™ Library Kit 2.0 (Thermo)
and Ion AmpliSeq PALB2 custom primers, comprising
27 primer pairs spanning 5.29 kb, were used to amplify
the coding regions of the PALB2 gene. Library concen-
trations and size distributions were determined with the
Qubit dsDNA HS Assay Kit (Thermo) and a High Sensi-
tivity DNA Analysis Kit on a Bioanalyzer 2100 (Agilent),
respectively.
Up to 48 libraries were combined in equimolar con-
centrations following their loading onto an Ion Chef for
DNA template preparation with a set of reagents from
an Ion PGM IC 200 Kit and an Ion 316 Chip Kit v2 BC
(Thermo). Sequencing was performed on the Ion
Torrent PGM in a mode with 500-flow runs. Data were
analyzed on the Ion Torrent server using the Torrent
Suite software (Thermo). Sequencing reads were aligned
to the hg19 reference genome and fitted to PALB2
designed amplicons. The coverage analysis and variant
caller plug-ins were run with optimal settings to identify
germline variants. PALB2 gene variants were annotated
using data from ClinVar-NCBI and LOVD.
TaqMan genotyping
Mutations found with NGS were validated by Sanger
sequencing. Furthermore, eight selected variants, namely
172_175del4, c.347insT, c.509_510delGA, Gln559Arg,
Glu672Gln, Leu939Trp, Gly998Glu, and Thr1100Thr
were analyzed using TaqMan SNP Genotyping Assays
(Thermo) on an ABI 7900HT qPCR system (Thermo),
as previously described [28].
Results
NGS analysis
We evaluated the frequencies of PALB2 germline muta-
tions in 460 BRCA1/2-mutation negative breast and/or
ovarian cancer patients. Of the 460 women, 268 had
HBC and/or HBOC, and 192 had EOBC, with a median
age at breast cancer diagnosis of 43 years (range 17–68
years).
In this group, we identified seven unrelated carriers
(1.5%) of the three PALB2 truncating mutations:
c.172_175delTTGT (n = 4), c.347insT (n = 1), and
c.509_510delGA (n = 2) (Table 1). Six of the seven
carriers (2.2%) were among the 268 HBOC patients, and
one (0.5%) was in the EOBC group.
In addition to these pathogenic mutations, we
detected 10 SNVs in the coding region of the PALB2
gene (Table 2).
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Genotyping of selected variants detected by NGS
Using TaqMan SNP genotyping assays, the frequencies of
eight selected variants, including three truncating muta-
tions (c.172_175delTTGT, c.347insT, c.509_510delGA), a
rare missense variant (Leu939Trp), and four common
polymorphisms (Gln559Arg, Glu672Gln, Gly998Glu,
Thr1100Thr), were tested in an additional group of 807
breast and/or ovarian cancer patients (median age, 48
years; range 20–85 years), and 1690 healthy women
(median age, 58 years; range 26–79 years).
The pathogenic mutation, c.172_175delTTGT, was iden-
tified in 4/807 (0.5%) breast cancer patients and in 4/1690
(0.24%) healthy controls (Table 2). The c.509_510delGA
mutation was detected in four breast cancer patients, and
was not found in healthy control subjects. The c.347insT
mutation was identified in neither additional cancer pa-
tients nor healthy controls.
The frequencies of the four common polymorphisms
were similar in cancer patients and healthy controls;
therefore, the clinical significance of these polymorphic
variants could not be confirmed. In addition, the
Leu939Trp missense variant was detected in six of 807
(0.7%) cancer patients and three of 1690 (0.2%) healthy
controls; hence, the incidence of this change was not
significantly different between patients and controls.
Discussion
We identified three pathogenic PALB2 mutations among
460 BRCA1/2-mutation negative breast and/or ovarian
cancer patients. The two recurrent mutations identified in
our study were c.172_175delTTGT and c.509_510delGA.
The novel pathogenic mutation c.347insT was found only
in one young patient with HBC. The two recurrent
mutations were identified in five patients with HBC
and one patient with EOBC, but without any family
history. In the cancer patient group, the recurrent
variants (c.172_175delTTGT and c.509_510delGA)
accounted for 86% (6/7) of PALB2 mutations. Our
NGS and TaqMan genotyping studies indicate that
the pathogenic c.509_510delGA mutation contributes
to familial breast and/or ovarian cancer (0.9%);
however, the c.172_175delTTGT mutation was
identified both in familial (0.6%) and non-familial can-
cer patients (0.7%). The recurrent mutation
c.509_510delGA is a European founder mutation that
has been identified in breast cancer patients from
Poland, Belarus, Russia, and Germany [16, 17, 24, 25].
This mutation has been detected in 0.6–1.4% of
breast cancer patients in three independent studies in
Poland [5, 16, 26]. The other recurrent PALB2 muta-
tion, c.172_175delTTGT, was identified in breast
cancer patients from the Czech Republic and Poland
[5, 18, 26].
The PALB2 gene mutation rate (1.5%) determined for
our group of breast and/or ovarian cancer patients was
similar to those reported by other studies. PALB2 germ-
line mutations have been identified in Finland, Germany,
Poland, Czech Republic, Russia, Italy, Spain, Australia,
United Kingdom, France, Netherlands, Canada, USA,
China, and South Africa, with rates ranging from 0.1 to
3.9%, depending on the population [15–27]. In breast
cancer families with both female and male breast cancer,
PALB2 mutation rates increased to 6.7% in a UK study
and to 9.0% in a Spanish study [12, 15].
In addition to clearly pathogenic mutations, we
detected 10 missense variants in the coding region of
the PALB2 gene. Identifying variants of unknown signifi-
cance in cancer susceptibility genes represents a real
problem in genetic counseling [30]. It should be stressed
that, to date, no PALB2 missense variant has been classi-
fied as definitely pathogenic in any large population
study [31]. Park et al. reported that the rare missense
variant, Leu939Trp, is associated with altered direct
binding of PALB2 to the RAD51C, RAD51, and BRCA2
proteins [32]. Functionally, the Leu939Trp mutant dis-
plays a decreased capacity for DNA double-strand break
repair and an increased cellular sensitivity to ionizing
radiation. In our group of breast and/or ovarian cancer
patients, the missense variant, Leu939Trp, was detected
in two (0.4%) breast cancer patients, one (0.4%) patient
with HBOC, and in one (0.5%) with EOBC. Interestingly,
in our study, the missense variant rate was 3.5 times
Table 1 Truncating and putative pathogenic missense mutations in the PALB2 gene revealed by NGS of samples from 460 breast
cancer patients
Exon PALB2 cDNA change Protein change Age at diagnosis (years) Family history
3 c.172_175delTTGT p.Gln60Argfs BR62 I- BR63, II- BR70
BR48 I- BR58
BR30 I- GC68, II- THYR60
BR40 I- BR50, MEL60, PR85
4 c.347insT p.Leu116fs BR40 Not reported
c.509_510delGA p.Arg170Ilefs BR59 I- BR66, II- BR40
BR32 I- BR38
I and II indicate first and second degree relatives, respectively; BR breast cancer, GC gastric cancer, THYR thyroid cancer, MEL melanoma, PR prostate cancer
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more frequent in breast cancer patients (0.7%) than in
healthy controls (0.2%), although the differences were
not statistically significant. Consistent with this observa-
tion, a recent large case-control study by Southey et al.
found no evidence of association of the Lys939Trp vari-
ant with breast cancer risk [33]. Furthermore, Catucci
and colleagues [34] have also recently shown that the
Lys939Trp variant does not disrupt the homologous
recombination-mediated DNA repair activity of PALB2
and they concluded that this variant should be regarded
as neutral with no clinical relevance to risk of breast
cancer.
Conclusions
In summary, our study confirmed two PALB2 recurrent
mutations, c.172_175delGA and c.509_510delGA, in
BRCA1/2-mutation negative breast and/or ovarian can-
cer patients from Poland. The c.509_510delGA mutation
contributed to familial cancer but was absent in non-
familial cancer patients, while the c.172_175delTTGT
mutation was identified in both familial and non-familial
cancer patients.
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